



MAYNE PHARMA LAUNCHES AMIODARONE TABLETS 200MG IN THE UNITED STATES

17 April 2018, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of amiodarone tablets, 200mg in the United States. Amiodarone is a generic alternative to Cordarone® tablets, indicated for life-threatening recurrent ventricular arrhythmia. This launch complements the existing amiodarone product range that includes 100mg and 400mg dose strengths.

Mayne Pharma's CEO, Mr Scott Richards, said "Amiodarone tablets are one of the first products to be manufactured at our new Greenville, North Carolina manufacturing facility which was recently completed. This new solid oral dose manufacturing facility quadruples the Company's US manufacturing capacity to well over 1 billion doses and importantly introduces significant capacity to manufacture potent compounds and new capability to manufacture modified-release bead/pellet products."

Mayne Pharma directly markets more than 55 products and has a growing pipeline of more than 30 generic and branded drug products targeting US markets with IQVIA sales greater than US\$5 billion. According to IQVIA, US brand and generic sales of amiodarone tablets, 200mg, were approximately US\$22 million for the 12 months ending 31 January 2018.

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

Cordarone® is a registered trademark of Sanofi.